p53 and breast cancer

被引:18
作者
Ziyaie, D [1 ]
Hupp, TR [1 ]
Thompson, AM [1 ]
机构
[1] Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland
关键词
D O I
10.1054/brst.2000.0199
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
p53 mutation is the most common genetic abnormality found so far in human cancer, and in breast cancer p53 mutation/alteration is seen in up to 50% of primary carcinomas. Together with the increasing knowledge of the characteristics and understanding of the role of p53 over the last two decades, attention in recent years has been focused on how this knowledge can be used in clinical settings for patient care and management in terms of analyzing p53 as a potential marker for studying the relationship between p53 expression and tumour development, progression and outcome; and designing alternative treatment strategies specifically aimed at restoring normal p53 function. (C) 2000 Harcourt Publishers Ltd.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 109 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]   The p53 network [J].
Agarwal, ML ;
Taylor, WR ;
Chernov, MV ;
Chernova, OB ;
Stark, GR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (01) :1-4
[3]   ESTROGEN-RECEPTOR STATUS - IMPORTANT VARIABLE IN PREDICTING RESPONSE TO ENDOCRINE THERAPY IN METASTATIC BREAST-CANCER [J].
ALLEGRA, JC ;
LIPPMAN, ME ;
THOMPSON, EB ;
SIMON, R ;
BARLOCK, A ;
GREEN, L ;
HUFF, KK ;
DO, HMT ;
AITKEN, SC ;
WARREN, R .
EUROPEAN JOURNAL OF CANCER, 1980, 16 (03) :323-331
[4]   HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].
ALLRED, DC ;
CLARK, GM ;
TANDON, AK ;
MOLINA, R ;
TORMEY, DC ;
OSBORNE, CK ;
GILCHRIST, KW ;
MANSOUR, EG ;
ABELOFF, M ;
EUDEY, L ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605
[5]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[6]   ALTERATIONS OF THE TP53 GENE AS A POTENTIAL PROGNOSTIC MARKER IN BREAST CARCINOMAS - ADVANTAGES OF USING CONSTANT DENATURANT GEL-ELECTROPHORESIS IN MUTATION DETECTION [J].
ANDERSEN, TI ;
BORRESEN, AL .
DIAGNOSTIC MOLECULAR PATHOLOGY, 1995, 4 (03) :203-211
[7]   Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21(WAF1) [J].
Ball, KL ;
Lain, S ;
Fahraeus, R ;
Smythe, C ;
Lane, DP .
CURRENT BIOLOGY, 1997, 7 (01) :71-80
[8]   MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].
BARAK, Y ;
JUVEN, T ;
HAFFNER, R ;
OREN, M .
EMBO JOURNAL, 1993, 12 (02) :461-468
[9]   Mechanisms of p53-mediated apoptosis [J].
Bates, S ;
Vousden, KH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :28-37
[10]   Therapeutic targeting of the p53 tumor suppressor gene [J].
Beaudry, GA ;
Bertelsen, AH ;
Sherman, MI .
CURRENT OPINION IN BIOTECHNOLOGY, 1996, 7 (06) :592-600